Bio-Rad Laboratories, Inc.’s (BIO) solid momentum in the QX600 Droplet Digital PCR (ddPCR) platform is poised to help it grow in the upcoming quarters. The clinical diagnostics business sees increased demand for quality control products, boosting its growth. Furthermore, the company’s emphasis on international expansion bodes well.  Yet, a soft Biopharma segment and macro-driven pressures on Bio-Rad’s margins raise worries.In the past year, shares of this Zacks Rank #2 (Buy) company have soared 13.3% compar ...